Today: 2 February 2026
Subscribe
Browse Category

NASDAQ:MIST News 12 December 2025 - 15 December 2025

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) entered a new phase in its corporate life this month: from clinical-stage story stock to a company with an FDA-approved, commercially launchable cardiovascular product. The catalyst is CARDAMYST™ (etripamil) nasal spray, now approved in the U.S. for adults experiencing acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT)—a rapid heart rhythm disturbance that can be frightening,…
15 December 2025
·····
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) Milestone Pharmaceuticals Inc. (NASDAQ: MIST) closed out the week in the spotlight after the company announced U.S. FDA approval of CARDAMYST™ (etripamil)—positioning Milestone to transition from a development-stage biotech to a commercial-stage cardiovascular company. GlobeNewswire The stock action was anything but calm. MIST closed at $2.41 on Dec. 12, down 18.31%, after…
14 December 2025
·····
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Updated: December 13, 2025 Milestone Pharmaceuticals Inc. (Nasdaq: MIST) just crossed the line that separates “clinical-stage story stock” from “commercial execution stock.” Late Friday, the company announced FDA approval of CARDAMYST™ (etripamil)—a self-administered nasal spray for adults to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. GlobeNewswire And because markets love drama, MIST didn’t celebrate with…
13 December 2025
····
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Updated: December 12, 2025Company: Milestone Pharmaceuticals Inc. ( NASDAQ: MIST ) Milestone Pharmaceuticals Inc. stock is drawing heightened attention on December 12, 2025 , as investors position ahead of a make-or-break FDA decision for the company’s lead program, CARDAMYST™ (etripamil) nasal spray , aimed at treating paroxysmal supraventricular tachycardia (PSVT) . The regulatory catalyst arrives after a volatile year that…
12 December 2025
·····

Stock Market Today

  • Hedge Funds Increase Southern Company (SO) Holdings by 3.83% in Latest 13F Filings
    February 2, 2026, 10:27 AM EST. Recent 13F filings for the 03/31/2025 period reveal that 14 hedge funds hold Southern Company (SO). Among these, five increased and five decreased their positions since 12/31/2024. Aggregate shares held by hedge funds rose by approximately 3.83%, with a net addition of 1.13 million shares, climbing from 29.39 million to 30.52 million shares. While 13F reports disclose only long positions, making it hard to see full market sentiment, collective trends offer insights. This rise in holdings highlights interest in SO among institutional investors, warranting further research. Observers will watch future 13F filings to track shifts in hedge fund strategies regarding Southern Company and potential stock opportunities.
Go toTop